Jonathan Stutters

Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial

Jeremy Chataway, Floriana De Angelis, Peter Connick et al. · The Lancet Neurology · 2020 · 124 citations · Full text

Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study

J William L Brown, Nick Cunniffe, Ferrán Prados et al. · The Lancet Neurology · 2021 · 89 citations · Full text

Relapsing-remitting Multiple Sclerosis, Medicine, Clinical Neurology +7

Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study

Hans-Peter Hartung, Bruce Cree, Maria Pia Sormani et al. · Multiple Sclerosis Journal · 2021 · 75 citations · Full text

Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis

Peter Connick, Floriana De Angelis, Richard Parker et al. · BMJ Open · 2018 · 56 citations · Full text

Slowly expanding lesions relate to persisting black-holes and clinical outcomes in relapse-onset multiple sclerosis

Alberto Calvi, Carmen Tur, Declan Chard et al. · NeuroImage Clinical · 2022 · 50 citations · Full text